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Short summary 
This work demonstrates the feasibility of an eight-channel dual-tuned transceiver 
surface radiofrequency (RF) coil array for combined 1H/19F magnetic resonance (MR) of 
the human knee at 7.0 Tesla following application of 19F-containing drugs. The benefits 
of such improvements are in positive alignment with the needs of explorations that are 
designed to examine the potential of 19F MR to trace and quantify 19F-containing drugs. 
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Abstract 
Purpose: 
To evaluate the feasibility of an eight-channel dual-tuned transceiver surface 
radiofrequency (RF) coil array for combined 1H/19F magnetic resonance (MR) of the 
human knee at 7.0 Tesla following application of 19F-containing drugs. 
Materials and Methods: 
The 1H/19F RF coil array includes a posterior module with two 1H loop elements 
and two anterior modules, each consisting of two 19F and one 1H element. The 
decoupling of neighbor elements is achieved by a shared capacitor. Electromagnetic 
field simulations were performed to afford uniform transmission fields and to be in 
accordance with RF safety guidelines. Localized 19F MRS was conducted with 47 and 
101 mmol/L of flufenamic acid (FA) – a 19F-containing non-steroidal anti-inflammatory 
drug (NSAID) – to determine T1 and T2 and to study the 
19F signal-to-dose relationship. 
The suitability of the proposed approach for 1H/19F MR was examined in healthy 
subjects.  
Results: 
Reflection coefficients of each channel were <-17 dB and coupling between 
channels was <-11 dB. The QL/QU was <0.5 for all elements. MRS results demonstrated 
signal stability with 1% of variation. T1 and T2 relaxation times changed with 
concentration of FA: T1/T2 = 673/31 ms at 101 mmol/L and T1/T2 = 616/26 ms at 47 
mmol/L. A uniform signal and contrast across the patella could be observed in proton 
imaging. The sensitivity of the RF coil enabled localization of FA ointment administrated 
to the knee with an in-plane spatial resolution of (1.5 × 1.5) mm2 achieved in a total 
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scan time of approximately three minutes, which is well suited for translational human 
studies.  
Conclusion: 
This study shows the feasibility of combined 1H/19F MRI of the knee at 7.0 T and 
proposes T1 and T2 mapping methods for quantifying fluorinated drugs in vivo. Further 
technological developments are necessary to promote real-time bioavailability studies 
and quantification of 19F-containing medicinal compounds in vivo. 
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Introduction 
Fluorine magnetic resonance (19F MR) is a valuable tool for in vivo tracking and 
quantification of fluorine-containing exogenous agents, such as emulsified 
perfluorcarbon tracer or 19F labeled cells (1-6). The biological abundance of fluorine is 
negligible. It is mainly present in inorganic form exhibiting very short T2 relaxation time 
and therefore low MR detection by MR systems. This virtual absence of fluorine in body 
tissue yields background free images with complete signal selectivity and specificity. 
One favorable characteristic of 19F is the relative large chemical shift for organic fluorine 
compounds spanning a range larger than 250 ppm (7-10), such that resonances of 
multiple 19F nuclei can be easily separated (11). 19F MR has become increasingly 
important for small animal imaging in multiple fields of pre-clinical research. Pioneering 
applications include non-invasive imaging of transplanted neural stem cells (12), early 
detection of acute allograft rejection (13,14), observation of intracellular oximetry (15), 
monitoring of cancer therapy (16,17), and assessment of cardiovascular, neurovascular 
and bowel diseases (5,18-22).  Due to the MR characteristics, 19F MR approaches 
would be potentially valuable for studying the pharmacokinetics of 19F-containing drugs 
and other compounds (23).  
The sensitivity limit for 19F detection constitutes an impediment for translational 
research and clinical applications (7). The limited number of reports referring to 19F MR 
in humans is an inherent testament to the practical obstacles of in vivo 19F MR (24-28). 
This state-of-affairs suggests that in vivo assessment of 19F content at magnetic field 
strengths of B0 ≤ 3.0 T is challenging, if not elusive, due to signal-to-noise, sensitivity 
and reproducibility constraints. Realizing these limitations and the intrinsic sensitivity 
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gain at higher magnetic field strengths (29-40) it is conceptually appealing to pursue in 
vivo 19F MR at ultrahigh field (UHF) strengths (B0 ≥ 7.0 T) with dedicated hardware.  
Dual-tuned radiofrequency (RF) coils have facilitated 19F MR experiments by 
enabling co-registration of 1H anatomical images and 19F informational images/spectra 
without replacing single tuned RF coils or RF coil retuning when switching imaging 
nucleus, avoiding sample displacement or RF coil sensitivity change. Several 
approaches can be found in literature that details improvement of this technology for 19F 
application (20,41-43). In this work we propose a modular dual-tuned 1H/19F eight 
channel (four proton channels and four fluorine channels) transceiver RF coil array 
tailored for knee imaging to examine the feasibility of human 1H/19F MR at 7.0 T. Array 
assembly provides high sensitivity, as it is placed close to the patient, and allows 
transmit field (B1
+) shaping by adjusting magnitude and phase of different channels to 
avoid B1
+ inhomogeneities at UHF. 
Electromagnetic field simulations (EMF) are conducted to carefully assess the 
performance of the proposed transceiver RF coil array. 19F MR signal-to-dose 
quantification is performed in phantoms using an ointment containing flufenamic acid 
(FA) – a 19F-containing non-steroidal anti-inflammatory drug (NSAID). The suitability of 
the proposed approach for 19F MR following topical application of a flufenamic acid 
ointment is demonstrated in a pilot volunteer study, as a precursor to broader clinical 
studies. The merits and limitations of the proposed approach are considered and their 
implications for in vivo drug bioavailability studies at 7.0 T are discussed. 
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Experimental 
RF coil design  
An eight-channel transceiver RF coil array tailored for combined 19F and 1H MR 
of the human knee at 7.0 T was built upon a modular design (44). The RF coil 
comprises three modules (Figure 1a): a posterior module with a curvature radius of 
11.5 cm to conform to an average size of the knee’s popliteal fossa, and two curved 
anterior modules (curvature radius = 10 cm) to cover the anterior knee anatomy. The 
posterior module consists of two rectangular loop elements tuned to 1H (f = 297.0 MHz) 
(Figure 1b). Each posterior element constitutes a loop size of (18 × 9.5) cm2 to support 
coverage of the posterior part of the knee. Each anterior module accommodates three 
square loop elements (Figure 1c) arranged into a triangular design to facilitate 
decoupling of neighboring elements. The two elements located above the knee were 
tuned to 19F (f = 279.5 MHz). The lateral element was tuned to 297.0 MHz to support 
coverage and signal homogeneity of anatomic 1H MR. The loop size of each anterior 
element was set to (5 × 5) cm2. The modules were assembled to geometrically fit with 
each other and to accommodate an average geometry of the knee.  
The structures shown in Figure 1 were milled onto printed circuit boards (PCB) 
using a computer numerical control (CNC) machine Promat S100 (LpKF, Garbsen, 
Germany). Decoupling between adjacent elements was achieved by a common 
conductor with a sharing decoupling capacitor (Figure 1b-c). The conductor width was 
set to 10 mm to minimize ohmic losses, and capacitive shortening was used for 
segmentation of the conductor (Figure 1b-c). Non-magnetic and PTFE-free trim 
9 
 
capacitors (Temex-Ceramics, Pessac, France) and ceramic capacitors (American 
Technical Ceramics Inc., Huntington Station, NY, USA) were used for tuning, matching 
and subdividing the loops in short sections, less than λ/10. The locations of the 
capacitors were given by the principal decoupling scheme or were placed to maintain 
symmetry over all elements. Chip capacitors with a capacitance of 22 pF were used on 
anterior modules, and chip capacitors with 2.2 and 2.7 pF were used on posterior 
module. Variable capacitors were used for all shared capacitors and tune/match 
capacitors.   
A cable trap was placed in the feeding cable of each loop element (Figure 1a) to 
suppress unbalanced currents on the coax cables. The cable traps were incorporated 
into the RF coil casing. The parallel resonant trap circuit is formed by a capacitor and a 
two-turn solenoid inductor of the feeding coaxial cable itself (45). The capacitor was 
soldered to the outer conductor of the cable to tune the cable trap to 19F or 1H 
frequency. 
A solid casing was designed for all three modules (Figure 2a). The RF coil 
casing was made from acrylonitrile butadiene styrene (ABS) using a 3D prototyping 
system (BST 1200es, Dimension Inc., Eden Prairie, MN, USA). The RF coil casing was 
designed to accommodate and secure all components of the modules including the 
curvatures of the posterior or anterior RF coil elements. The design was developed with 
the CAD software Autodesk Inventor 2010 (Autodesk Inc., San Rafael, CA, USA). The 
casing yields a distance of 10 mm between tissue and the RF coil, avoiding tissue 
heating caused by high electric fields in the vicinity of conductors and capacitors.  
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Hardware 
The RF characteristics of the RF coil were examined using an 8-channel vector 
network analyzer (ZVT 8, Rohde & Schwarz, Memmingen, Germany). Measurements of 
the full set of scattering parameters (S-parameters), which determine the reflection as 
well as coupling between the loop elements were conducted.  
MR experiments were conducted using a 7.0 T whole body MR scanner 
(Magnetom, Siemens Healthcare, Erlangen, Germany), equipped with (i) a gradient 
system that offers a maximum slew rate of 200 mT/m/ms and a maximum gradient 
strength of 40 mT/m (Avanto, Siemens Medical Solutions, Erlangen, Germany) and (ii) 
an 8 kW single channel RF amplifier (Stolberg HF-Technik AG, Stolberg-Vicht, 
Germany).  
The amplifier output was split into 8 equal-amplitude signals by means of home-
built power splitters compiled to a splitting cascade from 1:2, 2:8. For this purpose, 
Wilkinson power splitters 1:2 and and two 1:4 were used in lumped element design that 
feature equal intensity and phase differences less than 5° at the outputs. Phase 
adjustments of each channel were implemented by phase-shifting coaxial cables 
incorporated in the appropriate position in the power splitting network. All 8 elements 
were connected to the RF system using multipurpose interface box with transmit/receive 
switches and integrated low-noise preamplifiers (Stark Contrast, Erlangen, Germany). 
Compatibility of the proposed RF coil array with a single feeding radiofrequency power 
amplifier (RFPA) or with an eight channel parallel transmission system is enabled by 
feeding RF signals into the corresponding stage of the splitting network. 
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Electromagnetic field simulations 
Electromagnetic field simulations including specific absorption rate (SAR) 
calculations were performed using the FDTD technique of SEMCAD X (Schmid & 
Partner Engineering AG, Zurich, Switzerland). For this purpose, a virtual model of the 
experimental version of the RF coil and its casing were placed around the knee of the 
human voxel model Duke (BMI: 23.1) from the Virtual Family (46). The anatomic 
position of the voxel model's knee was adapted to ensure a correct distance between 
the RF coil array and the voxel model. The voxel model was truncated in regions with a 
negligible influence on the RF fields allowing for a high resolution mesh in the target 
region (Figure 2b). The basic mesh resolution of (3 × 3 × 3) mm3 was locally refined to 
(0.3 × 0.4 × 0.7) mm3 to secure all electrical connections in the RF coil, resulting in a 
total mesh of 10.3 million cells. The feeding points of the elements were modeled as 
50 Ω ports. The resulting S-parameters were exported into Advanced Design System 
(Agilent Technologies, Santa Clara, CA, USA) where an S-parameter simulation was 
performed to find the optimal values for all capacitor used for conductor segmentation, 
tuning, matching and decoupling. The capacitor values were optimized with respect to 
the S-parameter simulation and were used as a starting point for the practical 
realization. SAR simulation was performed for the final configuration and phase settings 
used in in vivo measurements. For this, we chose as a total input power of 1 W as 
reference. Based on the obtained SAR values, the input power used during in vivo 
measurements was adjusted in accordance to IEC 60601-2-33 Ed.3 regulations (47). 
 
Phantom experiments for validation of EMF simulations  
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A phantom setup consisting of the three modules placed around a cylindrical 
phantom was used to validate the RF coil model of the EMF simulations. For this 
purpose, the cylindrical phantom (radius = 90 mm, length = 250 mm) was filled with 
agarose gel (20 g/L) doped with NaCl (3.33 g/L) and CuSO4 (0.74 g/L), mimicking the 
tissue dielectric properties of normal healthy knee (ϵr = 65, σ = 0.72 S/m). Absolute 
transmission field (B1
+) distributions of the individual RF coil elements derived from the 
EMF simulations were compared to maps of absolute B1
+ derived from measurements. 
RF transmission field mapping was conducted for a transversal slice placed through the 
center of the phantom using a Bloch-Siegert implementation (48) with TR = 100 ms, 
Fermi pulse, off-center frequency = 4 kHz, scan time = 13 s. The sequence employed 
double gradient echo acquisitions with echo times TE1 = 8 ms and TE2 = 11 ms to enable 
static magnetic field (B0) mapping (49). First- and second-order shims were adjusted 
using volume selective B0 shimming. B1
+ mapping was done offline using Bloch 
simulations in Matlab (MathWorks, Natick, MA, USA), considering B0 non-uniformities. 
Due to the proximity of Larmor frequencies of 1H and 19F, the B1
+ maps of the 19F 
elements were acquired at the 1H frequency and corrected offline by means of the S-
parameter values. All absolute B1
+ values were normalized to the root mean square 
value of the input power at the feeding point of the loop structure. The resolution of the 
simulated maps was adapted by interpolation to match the resolution of the measured 
B1
+ maps. B1
+ difference maps were computed pixel-by-pixel by calculating the 
difference between simulated and measured B1
+ values as a percentage of the 
simulated B1
+ value for each element. For the difference maps, regions with measured 
values of less than 5 µT/sqrt(kW) were omitted.  
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Transmission (B1
+) field shaping 
The B1
+ fields of proton elements 1-4 were extracted at 297.0 MHz from EMF 
simulations performed on the voxel model’s legs, and the fields of fluorine elements 5-8 
were extracted at 279.5 MHz. The two sets were post processed with MATLAB using 
the superposition principle to optimize the homogeneity of the overall proton and 
fluorine B1
+ fields of the RF coil. For this purpose, two regions in the center of the 
patella with a size of (i) (24 × 3 × 3) mm3 and (ii) (3 × 3 × 3) mm3 were selected as 
regions of interest (ROI) for proton and fluorine channels, respectively. The mean phase 
within the ROI of each channel was compensated so that all the channels were in 
phase, allowing a constructive interference that yields a more uniform B1
+ field in the 
target region. The resulting phase setting was used for all in vivo MR studies and for 
SAR assessment. 
 
19F MR spectroscopy 
For 19F MR single voxel spectroscopy (SVS), a SPECIAL (SPin ECho full 
Intensity Acquired Localized) implementation (50) was employed  to detail (i) the 
transmitter voltage needed to obtain maximum signal for SPECIAL, (ii) reproducibility of 
19F signals, (iii) T1 relaxation, (iv) T2 relaxation, and (v) the 
19F signal-to-dose 
relationship for a 19F-containing NSAID ointment (flufenamic acid (2-([3-(Trifluoromethyl) 
phenyl]amino)benzoic acid), STADA Arzneimittel AG, Bad Vilbel, Germany) at 7.0 T.  
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To determine the correct transmitter voltage needed to achieve the maximum 
signal for the SPECIAL sequence, a calibration curve was acquired with this sequence 
varying the reference transmitter voltage, with which the transmitter voltages of all RF 
pulses are scaled, from 38 V to 56 V on 76 µmol of flufenamic acid contained in an 
NMR tube (VMR International, Radnor, Pennsylvania, USA, outer diameter = 5 mm, wall 
thickness = 0.43 mm, height = 50 mm). From the acquired data, the transmitter voltage 
that provides maximum signal intensity was extrapolated. To examine the signal stability 
obtained with SVS using SPECIAL, ten independent consecutive measurements were 
performed with the optimal voltage derived from the calibration curve. 
 T1 and T2 relaxation times were determined for two concentrations of the 
flufenamic acid (FA) ointment: a) 101 mmol/L FA and b) 47 mmol/L FA. Both samples 
were contained in NMR tubes (outer diameter = 5 mm, wall thickness = 0.43 mm, height 
= 50 mm). T1 and T2 relaxation times were obtained for a voxel covering the sample 
using a voxel of size of (7 × 7 × 40) mm3. For T1 relaxation time measurements, TR was 
set to  260, 500, 750, 1000, 1250, 1500, 1750, 2000, 3000, 4000 and 5000 ms with TE 
= 5.5 ms, total scan time = (33-640) s, number of averages = 128. For T2 relaxation time 
measurements, TE was set to = 5.5, 8, 10, 12, 15, 30, 40, 60, 80, 100 and 120 ms for 
the 101 mmol/L FA sample. For the 47 mmol/L FA sample, TEs of 5.5, 9, 15, 20, 30, 40, 
50 and 60 ms were employed. For both FA concentrations, TR was set to 4000 ms with 
number of averages = 128 and total scan time = 512 s. To calculate the T1 and T2 
relaxation times for each sample, data were fitted to T1 and T2 relaxation equations 
using MATLAB. 
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For quantification of the signal-to-dose relationship, a flufenamic acid ointment 
with a concentration of 101 mmol/L was used. Increasing amounts of FA ranging from 
15.3 µmol to 76.5 µmol were achieved by increasing the voxel size of SPECIAL from (7 
× 7 × 9) mm3 to (7 × 7 × 45) mm3 using increments of 3 mm that correspond to 5 μmol. 
Measuring parameters were: TR = 2000 ms, TE = 5.5 ms. The number of averages was 
changed between 1032 and 40, according to the voxel size to assure similar signal-to-
noise ratio (SNR) for each measurement resulting in a total scan time ranging in 
between 512 s and  22 s. The acquired signal intensities were processed and fitted to a 
linear equation using MATLAB. 
 
Ethics statement 
All volunteer studies were performed after due approval by the local ethical 
committee (registration number DE/CA73/5550/09, Landesamt für Arbeitsschutz, 
Gesundheitsschutz und technische Sicherheit, Berlin, Germany). Informed written 
consent was obtained from each volunteer prior to the study. 
 
Pilot study in heathy volunteers  
In vivo knee imaging was performed in four healthy subjects (two male, two 
female, age = 24-31 years, BMI = 23 ± 1 kg/m2). A small amount of flufenamic acid 
containing ointment (equivalent to 245 μmol of flufenamic acid) was applied 
epicutaneously on the region of the patella. High spatial resolution 1H images of the 
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knee were acquired using a 2D gradient echo (GRE) technique with reference 
transmitter voltage = 100 V (corresponding to peak power of 200 W), nominal flip angle 
= 30°, TR = 10 ms, TE = 2.7 ms, in plane resolution = (0.8 × 0.8) mm2, slice thickness = 
5 mm, number of slices = 5, matrix size = 256 × 256, number of averages = 1 and total 
scan time = 10.8 s. 19F images of the flufenamic acid ointment were acquired using a  
2D GRE sequence and reference transmitter voltage = 65 V (corresponding to peak 
power of 84.5 W), nominal flip angle = 27°, TR = 90 ms, TE = 1.3 ms, in plane spatial 
resolution = (1.5 × 1.5) mm2, slice thickness = 5 mm, number of slices = 5, matrix = 128 
× 128, averages = 16, total scan time = 3.06 min. 19F images were threshold-filtered and 
superimposed to 1H images using ImageJ (NIH, Bethesda, MD, USA). 
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Results 
Hardware and RF characteristics  
The modules of the proposed RF coil are lightweight and conform to a broad 
range of knee geometries. Localized mechanical pressure is averted due to flexible 
arrangement of the modules. This leads to well perceived patient comfort and easy 
handling of the three modules. With a height of 31 mm, the modules consume minor 
space in the effective magnet bore.  
The RF coil could be conveniently adapted to various loading conditions 
governed by the phantom and the healthy subjects by changing the capacitance of the 
tuning, matching and decoupling of the trim capacitors. Changing the capacitance of the 
partition capacitors was not required. The S-parameter matrices for both 1H (Figure 3a) 
and 19F (Figure 3b) frequencies showed reflection coefficients (Sii) below -17 dB and 
transmission coefficients (Sij) lower than -11 dB. These values were obtained by 
averaging over five subjects (2 males, 3 females, age = 24-31, BMI = 21-30 kg/m2), 
after tuning and matching the RF coil to one individual subject. It demonstrated that the 
RF coil is not sensitive to various loads.  
The loaded (QL) and unloaded quality factor (QU) were obtained by loading and 
unloading the RF coil on a subject. The ratio between these values (QL/QU) was below 
0.5 for all RF coil elements, indicating the dominance of sample noise (Table 1). The 
load power absorption (1- QL/QU) was found to be 0.52-0.89 (Table 1), indicating that 
most of the RF energy generated by the RF coil is absorbed by the load.  
Overall losses from the system RF output to the individual RF coil connectors 
were determined to be -3.05 dB; the feeding cable from MR system interface to the 
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Wilkinson power splitters introduced -1.0 dB of loss, the Wilkinson power splitters 1:2 
and 1:4 -0.5 dB, the transmit/receive switches -1.5 dB, and coaxial cables -0.05 dB. 
These losses were found to be in accordance to another RF coil development study at 
7.0 T (44) and were considered for the input power calculation. Losses originating from 
the RF amplifier are calibrated automatically by the MR system, thus they are not 
considered. Phase cables were manufactured with less than ± 2° phase deviation. The 
overall variance for the phase adjustment was found to be less than ± 6°. 
 
Validation of EMF simulations in phantoms and B1
+ mapping  
The transmission fields obtained from EM simulations of individual RF coil 
elements placed on the virtual cylindrical phantom were found to be in good quantitative 
and qualitative agreement with the B1
+ fields derived from B1
+ mapping in phantom 
experiments as illustrated in Figure 4 for 1H elements 1-4 and 19F elements 5-8. Some 
artifacts can be detected in the measured B1
+ maps for elements 1 and 2, due to 
singularities in the Bloch algorithm when unwrapping phase caused by irregularities 
within the phantom. The difference map between simulated and measured B1
+ fields of 
individual elements is shown as relative difference in percent (Figure 4). For the 
transversal slice of the phantom, the overall mean difference between the mean B1
+ 
values obtained for simulations and measurements was found to be between -8.28% 
and  +1.15% for the eight channels. The percentile difference maps demonstrate the 
validity of the RF coil model and support the credibility of the SAR simulations.  
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B1
+ distribution after phase optimization 
The phase setting for each individual loop element was determined by 
transmission field shaping for a ROI placed in the patella. The derived phases (Table 2) 
were implemented in the human voxel model simulations to give rise to a uniform B1
+ 
distribution for 1H and 19F across the region of the patella as outlined in Figure 5. 
 
SAR simulations after phase optimization 
 The 10 g averaged local SAR distribution was determined for all 1H and 19F 
elements using the phases derived from transmission field shaping (Figure 6). The 
maximum 10 g averaged local SAR for the four proton loop elements at 1H frequency 
was found to be 0.65 W/kg for 1 W of input power. Using the same power settings, the 
maximum 10 g averaged SAR for the four fluorine elements at 19F frequency was 1.76 
W/kg. Considering -3.05 dB of hardware losses, these findings were used to limit the 
maximum input power used in in vivo experiments to 22 W, to stay within the 20 W/kg 
SAR limit specified by the IEC guidelines for body extremities at normal operating mode 
(47). The first and second level controlled mode given by the IEC guidelines (47) were 
not used in the in vivo applications which limits the maximum local 10 g SAR to 40 W/kg 
and thus preserves a safety margin of factor 2. 
19F MR spectroscopy   
To determine the correct transmitter voltage, a calibration curve was acquired 
using reference transmitter voltages ranging from 38 V to 56 V (corresponds to peak 
power of 28.9 to 62.7 W). For this purpose, SVS using the fluorine loop elements (5-8) 
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together with an NMR tube containing 76 µmol FA was performed. The reference 
transmitter voltage for obtaining maximum 19F signal using SPECIAL sequence was 
found to be 44 V (corresponding to 38.8 W peak power) (Figure 7a).  
To determine the reproducibility of the 19F signal, ten acquisitions were then 
performed using the transmitter voltage of 44 V. For this reference transmitter voltage, a 
mean signal intensity of 3.94 ± 0.04 (a. u.) was observed for the 19F signal. This 
translates into a signal variation of 1% (Figure 7b).  
To scrutinize the 19F signal-to-dose relationship for flufenamic acid, SVS was 
performed.  For this purpose, increasing amounts of FA ranging from 15.3 µmol to 76.5 
µmol were used. The signal-to-dose quantification curve is shown in Figure 7c. The 
slope of the curve yielded a signal-to-dose relationship of 0.05 arbitrary signal per µmol 
FA with a linear regression coefficient of 0.99. 
 T1 and T2 relaxation times were examined for FA concentrations of 101 mmol/L 
and 47 mmol/L. A longitudinal relaxation time of T1 = 616 ms was observed for a 
concentration of 47 mmol/L FA (Figure 8a). A concentration of 101 mmol/L FA yielded 
T1 = 673 ms (Figure 8a). A transversal relaxation time of T2 = 31 ms was deduced for a 
concentration of 101 mmol/L FA. A concentration of 47 mmol/L FA revealed a T2 
relaxation time of 26 ms (Figure 8b).  
 
Pilot study in healthy volunteers  
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For the pilot study in healthy volunteers, all eight elements of the proposed 
modular 1H/19F transceiver array were exploited. Figure 9 surveys transversal 1H and 
19F views of the knee for all subjects. The RF coil design supported anatomic 1H 2D 
GRE imaging which provided uniform signal and contrast across the patella by applying 
the phase settings derived from the transmission field shaping procedure. A spatial 
resolution of (0.8 × 0.8 x 5.0) mm3 was achieved in a scan time of 11 s (Figure 9, left 
column). The proposed transceiver array facilitated 19F 2D GRE imaging of the FA 
ointment using a spatial resolution as high as (1.5 × 1.5 x 5.0) mm3, which was 
accomplished in a total scan time of approximately three minutes (Figure 9, middle 
column). The overlay of 19F images in red and 1H anatomical images in gray scale 
provides visualization of the FA ointment at the area of topical application (Figure 9, 
right column).  
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Discussion 
This study adds to the literature by demonstrating that the proposed modular 
eight channel 1H/19F transceiver RF coil array supports proton and fluorine MR of the 
human knee and fluorinated drugs at 7.0 Tesla. The sensitivity of the proposed RF coil 
array enabled 19F localization following epicutaneous administration of a 19F-containing 
NSAID ointment to the human knee. The in-plane spatial resolution was as high as (1.5 
× 1.5) mm2. This spatial fidelity was accomplished in a total scan time of approximately 
three minutes, which is very well suited for translational human studies and for clinical 
applications. These findings indicate that 19F MR may represent a potentially useful 
resource for studying the distribution and bioavailability of 19F-containing drugs in 
clinical trials.  
Beside patient comfort and flexibility to accommodate a broad range of knee 
sizes, the RF characteristics of the proposed RF coil are encouraging and suggest that 
subject-specific tuning and matching may not be necessary when used in a clinical 
setting. However, as every sensitivity gain is crucial for 19F MR, the RF coil should be 
properly tuned and matched for each loading condition. This could be conveniently done 
on the phantom and different subjects studied here by changing the capacitance of the 
tuning, matching and decoupling of the trim capacitors. The Q-factor ratio of all 
elements was below 0.5, indicating a sample noise dominance, which is desirable for 
achieving higher SNR. 
 The proposed transceiver array encourages further explorations into densely 
packed multi-channel transceiver RF coil arrays tailored for 19F MR. With appropriate 
single or multi transmit systems, one might envisage the implementation of 19F RF coil 
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arrays tailored for knee MRI with even more than eight transmit/receive elements. This 
vision continues to motivate new research on integrated multi-channel systems (51) and 
on RF coil design together with explorations into ideal current patterns (52) in order to 
yield the best possible SNR for UHF-MR. The field is in a state of creative flux and 
future solutions will involve designs that use different building blocks for signal 
transmission and reception in order to balance the constraints dictated by sensitivity, 
depth penetration, transmission field uniformity and SNR (53). In this context, a recent 
report suggested the combination of dipole antenna for excitation and loop elements for 
reception (53). In addition, recent considerations outlined that loop and dipole current 
patterns contribute equally to ultimate intrinsic SNR at 7.0 T (52,54). For field strengths 
of B0 ≥ 9.4 T, current patterns are dominated by linear (dipole type) current patterns 
(52,54), which provides motivation for shifting the weight to dipoles versus loop 
elements. With this in mind, moving toward magnetic field strengths of B0 = 9.4 T and 
higher holds the promise for improved spatial resolution and sensitivity during 
quantitative 19F MR studies.   
Our 19F SVS phantom studies with flufenamic acid showed a steady 19F signal 
over a series of independent measurements with a signal variability of 1%. A closer 
examination revealed a detection limit of 15.3 μmol corresponding to ~9.2 × 1018 19F 
spins for the proposed setup. Notwithstanding this success, SVS at 7.0 T remains 
challenging since it is prone to B0 inhomogeneities, requires extra shimming 
adjustments and builds upon sophisticated offline post-processing. B0 inhomogeneities 
at 7.0 T also make SVS vulnerable to partial volume effects. One option to overcome 
this shortcoming could be the use of multi-voxel spectroscopy (or chemical shift 
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imaging) that provides spatially resolved results (55) though at the expense of lower 
SNR (56). For more complex 19F molecular structures, optimized sequences that 
minimize J coupling effects and provide large RF bandwidths to reduce chemical shift 
artifacts will be required. One possible approach could be to perform sine-bell 
acquisition-weighted chemical shift imaging with selective refocusing pulses (5).  
Our phantom studies showed changes in T1 and T2 relaxation times with 
increasing concentrations of flufenamic acid. An increase in FA concentration of more 
than 200% resulted in an increase in T1 (109%) and T2 (120%) relaxation times. Other 
than changes in 19F concentration, spin-lattice relaxation rates (R1) of fluorinated 
compounds were also shown to be dependent on temperature and magnetic field 
strength (57). In biological tissue, T2 relaxation times of fluorinated anesthetic were 
reported to correlate with temperature and anesthetic potency (58). The binding 
capacity of drug to macromolecular sites also influences changes in T1 values; 
competitive binding for common binding sites strongly reduces the T1 relaxation for 
19F 
drugs (59). Therefore T1 and T2 mapping techniques can also be considered as 
important tools for detailing the profile of 19F-containing compounds.  
NSAIDs have been shown to have anti-inflammatory, analgesic, and antipyretic 
effects and when applied topically they are believed to reduce inflammation in 
muskuloskeletal disorders. These compounds have been shown to penetrate the 
human skin but no human in vivo studies have been carried out so far to study the 
distribution, let alone quantification, of active compound at the site of injury where the 
compound is acting. In this study we demonstrated the feasibility of tracking 19F-
containing NSAID in vivo at 7.0 T, which encourages further studies in patients suffering 
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from inflammatory conditions. It is conceivable, that the concentration of drug ultimately 
penetrating the skin to reach its site of action (in the case of NSAIDs, areas of 
inflammation) might be close to or even lower than the detection limit. In biological 
tissue, the NMR properties of 19F-containing drugs are also expected to change as has 
been previously reported for T1 (59) and T2 (58) relaxation times. This is due to several 
factors such as changes in the environment but also pharmacokinetic (e.g. degradation 
of parent compound) as well as pharmacodynamic processes (e.g. protein binding). In 
contrast to the present volunteer study, the 19F-containing topical NSAID is commonly 
applied up to three times daily in patients and over longer periods of time; an 
accumulation of active compound at its site of action is to be expected. This potentially 
increases the locally available quantities of drugs in vivo. However, it is still likely that 
the concentration of drug at the site of action to be too low for detection. The low 
availability of drug and low 19F signal sensitivity are indeed main limitations for drug 
targeting studies at the moment. In our healthy volunteer studies 19F 2D GRE imaging of 
substantial quantities of 19F-containing drug was achieved in a total scan time of 
approximately three minutes, which is well suited for translational human studies.  
Although the scan time could be moderately increased to accommodate for averaging in 
order to increase 19F signal, increasing the total scan time is generally undesirable. 
Apart from issues concerning patient comfort, longer scan sessions are also prone to 
motion artifacts. Especially for high spatially-resolved SVS quantification inaccuracies 
might also arise. Evolving MR measuring techniques such as compressed sensing 
might be valuable in the future to offset speed constraints for in vivo 19F MRI (60). 
Improved 19F spectroscopic techniques, perhaps less prone to B0 inhomogeneities and 
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chemical shift artifacts, will be a further challenge to overcome in order to quantify 19F 
drug in vivo. B1
+ field compensation techniques will be necessary to avoid possible 
incorrect 19F MR drug quantification as a result of B1
+ inhomogeneities when comparing 
drug spectra at the site of interest with standard drug reference spectra (61,62).  
 Although, accessing in vivo distribution and quantification of 19F-contained drugs 
presents several challenges, the preliminary findings of this 19F MR study at 7.0 T are 
encouraging and point towards the prospect of applying 19F MR and NSAID therapy to 
the field of theranostics with the ultimate goal to visualize and measure the 
concentration along with providing dosage guiding of a therapeutically-active compound 
reaching the inflammatory site in rheumatoid arthritis patients. While this is, for the 
moment, merely a gedankenexperiment, it continues to motivate new research and 
encourages further studies with patients suffering from inflammatory conditions. These 
pioneering efforts include 19F MR visualization (i) of collagen induced arthritic 
inflammation in small rodents upon invasive administration of a perfluorcarbon contrast 
agent as a means of studying therapeutic response (63) and (ii) of arthritic rabbit knees 
following intra-articular injection of a perfluoro-15-crown-5-ether emulsion (41). In light 
of a pioneering report on labeling dendritic cells (DCs) with a clinical-grade 19F label 
(perfluoro dialkyl ether, CS-1000, Celsense) and reintroduction in cancer patients (26), 
the modular design of our RF coil technology could be adapted for DC imaging with 
higher sensitivity at 7.0 T. In the recent proof-of-concept study, DCs were visualized at 
their site of application using combined 19F and 1H MR imaging at 3.0 T (26).  Although 
DCs could be clearly visualized at their site of application, there was no MRI evidence of 
cell accumulation in the draining lymph nodes (26), possibly due to cell densities in 
27 
 
these regions being on the order of, or below, the cell detection limit threshold for the 
experimental configuration employed (26). 
 In conclusion, this study showed the feasibility of 19F MRI of the knee after 
epicutaneous application of a 19F contained NSAID. The proposed modular eight 
channel 1H/19F transceiver RF coil array contributes to the technological basis for the 
clinical assessment of biodistribution and bioavailability of 19F-containing drugs. The 
results underscore the challenges of fluorine MR in humans and demonstrate that these 
issues can be offset by using tailored RF coil hardware. The benefits of such 
improvements would be in positive alignment with the needs of explorations that are 
designed to examine the potential of 19F MR to trace and quantify 19F-containing drugs. 
As 7.0 T UHF-MR applications become increasingly used for research, they should help 
to advance the capabilities of in vivo 19F MR for the assessment of the metabolic fate of 
19F-containing drugs.   
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Tables 
Table 1. Loaded quality factor (QL), unloaded Q factor (QU), ratio between QL and QU 
(QL/QU) and load power absorption (1- QL/QU) for each RF coil element. 
Nucleus  Element # Q loaded (QL) Q unloaded (QU) QL/QU 1- QL/QU 
1H 
1 12.91 59.4 0.22 0.78 
2 17.7 37.1 0.48 0.52 
3 15.4 62.5 0.25 0.75 
4 15.4 99.0 0.16 0.84 
19F 
5 25.4 93.2 0.27 0.73 
6 29.4 223.6 0.13 0.87 
7 27.3 248.4 0.11 0.89 
8 27.3 124.2 0.22 0.78 
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Table 2. Phase setting of each RF coil element. 
Nucleus  Element # Phase  
1H 
1 38° 
2 110° 
3 0° 
4 190° 
19F 
5 77° 
6 160° 
7 208° 
8 313° 
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Figures captions 
Figure 1 
a) Photograph of the proposed modular, eight channel transceiver RF coil array with the 
top casing being removed. The figure includes element nomenclature (numbers 1-8) 
and nuclei (1H/19F) identification. b) Basic loop structure for the posterior module 
including capacitor placement and capacitor values. c) Basic loop structure for the 
anterior module including capacitor placement and capacitor values. CD – decoupling 
capacitor, CM – matching capacitor, CT – tuning capacitor, trim – trim capacitors (1-13 
pF). 
  
Figure 2 
a) Photograph of the RF coil array conforming to the knee of a volunteer. b) An accurate 
model of the RF coil and the lower legs of the voxel model “Duke” used (46) for  the 
electromagnetic field  simulations.  
 
Figure 3 
Synopsis of the results derived from the assessment of the RF characteristics of the 
eight channel transceive 1H/19F RF coil array including S-parameter matrix averaged 
over five subjects (a) at 1H frequency (f = 297.0 MHz), and (b) at 19F frequency (f = 
279.5 MHz).   
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Figure 4 
Comparison of simulated and measured B1
+ maps for each element loop of the 
proposed RF coil array using a cylindrical phantom setup. a) For B1
+ evaluation, 
transversal slices of the cylindrical phantom were positioned in alignment with the 
center of the loop elements. Left column: Simulated and measured B1
+ maps of the 1H 
loop elements. B1
+ was normalized to maximum B1
+ of each element. Middle column: 
Simulated and measured B1
+ maps of the 19F loop elements. B1
+ was normalized to 
maximum B1
+ of each element. Due to the proximity of Larmor frequencies of 1H and 19F, 
the B1
+ maps of the 19F elements were acquired at the 1H frequency and corrected 
offline by means of the S-parameter values. Right column: B1
+ difference maps of the 
proton and fluorine elements. The measured maps were subtracted pixel-by-pixel from 
the simulated maps and normalized to the simulated maps. The results demonstrate the 
qualitative and quantitative agreement between the numerical simulations and the 
measurements. b) Positioning of the transversal slices with respect to the coil elements 
and to the phantom (coronal view). The blue dashed rectangle represents the phantom, 
the black dotted lines the transversal slice positioning and the numbers refer to element 
nomenclature. 
 
Figure 5 
Axial, sagittal and coronal views of the B1
+ distribution of the 1H and 19F elements of the 
proposed transceiver array for the male human voxel model Duke (46). To guide the 
eye, the loop elements of the anterior modules are shown in light grey and the loop 
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elements of the posterior module are marked in light green. The numbers refer to the 
element nomenclature. Phase setting of the elements was set to: element 1 = 38°, 
element 2 = 110°, element 3 = 0°, element 4 = 190°, element 5 = 77°, element 6 = 160°, 
element 7 = 208° and element 8 = 313°. The dotted lines describe the slices from which 
the B1
+ distribution views were obtained. 
 
Figure 6 
Axial, sagittal and coronal views of the maximum projection plots of the local 10 g 
averaged SAR distribution for the male human voxel model Duke based on the phase 
setting: element 1 = 38°, element 2 = 110°, element 3 = 0°, element 4 = 190°, element 5 
= 77°, element 6 = 160°, element 7 = 208° and element 8 = 313°. The loop elements of 
the anterior parts are shown in light grey and the loop elements of the posterior part are 
marked in in light green. The numbers refer to element nomenclature. The dotted lines 
describe the slices from which the views are obtained. 
 
Figure 7 
Synopsis of the phantom experiments using single voxel spectroscopy with a SPECIAL 
implementation (50). a) Transmitter voltage calibration curve showing signal intensity 
versus transmitter voltage and the extrapolated required transmitter voltage that 
provides maximum signal intensity for the SPECIAL sequence. b) Ten consecutive 
independent measurements with a transmitter voltage of 44 V. A mean signal intensity 
39 
 
of 3.94 ± 0.04 (a. u.) was observed for the 19F signal. c) Signal-to-dose quantification 
curve of the ointment containing flufenamic acid (FA). 
Figure 8  
Synopsis of the relaxation time measurements. T1 (a) and T2 (b) relaxation curves of 
concentrations 101 mmol/L and 47 mmol/L of FA.  
 
Figure 9 
Synopsis of the in vivo pilot study. Left: 1H axial views derived from gradient echo 
imaging the knees of four healthy subjects. A spatial resolution of (0.8 × 0.8 × 5.0) mm3 
was achieved. Center: Corresponding axial views of threshold filtered 19F GRE images 
following topical application of the FA ointment. A spatial resolution of (1.5 × 1.5 × 5.0) 
mm3 was accomplished. Right: Overlay of the 1H (grey scale) and 19F images (red). 
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